Grunenthal GmbH Presents a New Website for the Topical Treatment of Postherpetic Neuralgia (PHN)
5/22/2013 9:55:09 AM
More...
|
Grunenthal GmbH Highlights Significant R&D Advances in Pain, Inflammation as well as INTAC® Tamper-Resistant Technology at World's Largest Biotechnology Conference
4/19/2013 7:40:46 AM
More...
|
Grunenthal GmbH to Present Data for Its Innovative Formulation Technology INTAC® at PAINWeek 2012
9/6/2012 10:15:58 AM
More...
|
Grunenthal GmbH to Present Its Tamper Resistant Formulation Technology INTAC® at the Meeting & Exposition of the Controlled Release Society
7/13/2012 10:27:11 AM
More...
|
Horizon Pharma, Inc. Enters into Exclusive Agreement with Grunenthal GmbH for Commercialization of DUEXIS® in Latin America
6/19/2012 11:37:11 AM
More...
|
Grunenthal GmbH to Present at 2012 Biotechnology Industry Organization (BIO) International Convention on June 20, 2012, in Boston MA, US
6/15/2012 10:26:09 AM
More...
|
Grunenthal GmbH Presents Strong Pipeline at World's Largest Biotechnology Conference
6/14/2012 11:17:45 AM
More...
|
Grunenthal GmbH Release; Assessment of Abuse-Deterrent and Tamper-Resistant Technologies: From the Bench-Top to the Users
6/11/2012 10:37:49 AM
More...
|
Grunenthal GmbH Release: INTAC™ Technology Combats Misuse of Extended Release Drugs
5/16/2012 9:51:35 AM
More...
|
Grunenthal GmbH Release: Stronger! INTAC(TM) Formulation Technology Protects Intended Action of Extended Release Drugs
4/30/2012 11:53:10 AM
More...
|
|